Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: A secondary analysis of the Look AHEAD randomised clinical trial

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 10, 2014, Pages 801-809

  Bahnson, Judy L ^a   Knowler, W C ^b   Bantle, J P ^b   Bertoni, A G ^b   Bray, G A ^b   Chen, H ^b   Cheskin, L ^b   Clark, J M ^b   Egan, C ^b   Evans, M ^b   Foreyt, J P ^b   Glasser, S P ^b   Greenway, F L ^b   Gregg, E W ^b   Hazuda, H P ^b   Hill, J O ^b   Horton, E S ^b   Hubbard, V S ^b   Jakicic, J M ^b   Jeffery, R W ^b   Johnson, K C ^b   Kahn, S E ^b   Kitabchi, A E ^b   Korytkowski, M ^b   Krakoff, J ^b   Kure, A ^b   Lewis, C E ^b   Maschak Carey, B J ^b   Michaels, S ^b   Montez, M G ^b   Nathan, D M ^b   Nyenwe, E ^b   Patricio, J ^b   Peters, A ^b   Pi Sunyer, X ^b   Pownall, H ^b   Wadden, T A ^b   Wagenknecht, L E ^b   Williamson, D F ^b   Wing, R R ^b   Wyatt, H ^b   Yanovski, S Z ^b   more..

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ALBUMINURIA; ARTICLE; BEHAVIOR THERAPY; CALORIC RESTRICTION; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY DISEASE IMPROVING GLOBAL OUTCOMES; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATIENT EDUCATION; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SOCIAL SUPPORT; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; WEIGHT REDUCTION; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; WEIGHT LOSS PROGRAM;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; WEIGHT REDUCTION PROGRAMS;

EID: 84921437510     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70156-1     Document Type: Article

References (32)

1. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012, 380:1662-1673.
2. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013, 24:302-308.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The DCCT Research Group.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
5. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE Collaborative Group.
6. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010, 376:419-430.
7. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996, 276:1409-1415. The DCCT Research Group.
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
9. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154. for the Look AHEAD Research Group.
10. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003, 24:610-628. The Look AHEAD Research Group.
11. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring) 2006, 14:737-752. The Look AHEAD Research Group.
12. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) research study. Diab Vasc Dis Res 2006, 3:202-215. The Look AHEAD Research Group.
13. KDIGO clinical practice guideline for the valuation and management of chronic kidney disease. Kidney Int 2013, 3(suppl 3):1-150. Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease Work Group.
14. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612. for the Chronic Kidney Disease Epidemiology Collaboration.
15. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007, 30:1374-1383. The Look AHEAD Research Group.
16. Borch-Johnsen K, Andersen PK, Deckert T The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985, 28:590-596.
17. Nelson RG, Pettitt DJ, Carraher MJ, Baird HR, Knowler WC The effect of proteinuria on mortality in non-insulin-dependent diabetes mellitus. Diabetes 1988, 37:1499-1504.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
19. Lewis EL, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
20. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
21. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
22. Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O Mutifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
23. Ibrahim HN, Weber ML Weight loss: a neglected intervention in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2010, 19:534-538.
24. Long term effects of lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes: four year results of the Look AHEAD trial. Arch Intern Med 2010, 170:1566-1575. Look AHEAD Research Group.
25. Faulconbridge LF, Wadden TA, Rubin RR, et al. One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study. Obesity 2012, 20:783-793. for the Look AHEAD Research Group.
26. Foy CG, Lewis CE, Hairston KG, et al. Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial. Obesity 2011, 19:83-93. and the Look AHEAD Research Group.
27. Phelan S, Kanaya AM, Subak LL, et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol 2012, 187:947-952. and the Look AHEAD Research Group.
28. Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med 2012, 366:1209-1217. for the Look AHEAD Research Group.
29. Ribisl PM, Gaussoin SA, Lang W, et al. Lifestyle intervention improves heart rate recovery from exercise in adults with type 2 diabetes: results from the Look AHEAD study. J Obesity 2012, 2012:309196. and the Look AHEAD Research Group.
30. Redmon JB, Bertoni AG, Connelly S, et al. Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2010, 33:1153-1158. and the Look AHEAD Research Group.
31. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. The Action to Control Cardiovascular Risk in Diabetes Study Group.
32. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.